{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:13Z","timestamp":1794007333932,"version":"4.8.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute of Research, Development and Innovation, International Medical University, Kuala Lumpur, Malaysia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Invasive fungal infections are a potentially life-threatening complication in immunocompromised patients. The aim of this study was to assess the efficacy and safety of posaconazole as compared with other antifungal agents for preventing invasive fungal infections in immunocompromised patients. Embase, CENTRAL, and MEDLINE were searched for randomized conweekmonthtrolled trials (RCTs) up to June 2020. A systematic review with meta-analysis of RCTs was performed using random-effects model. Trial sequential analysis (TSA) was conducted for the primary outcome to assess random errors. A total of five RCTs with 1,617 participants were included. Posaconazole prophylaxis was associated with a significantly lower risk of IFIs (RR, 0.43 [95% CI 0.28 to 0.66, p\u2009=\u20090.0001]) as compared to other antifungal agents. No heterogeneity was identified between studies (I<jats:sup>2<\/jats:sup>\u2009=\u20090%). No significant associations were observed for the secondary outcomes measured, including risk reduction of invasive aspergillosis and candidiasis, clinical failure, all-cause mortality, and treatment-related adverse events, except for infection-related mortality (RR, 0.31 [95% CI 0.15 to 0.64, p\u2009=\u20090.0001]). Subgroup analysis favoured posaconazole over fluconazole for the prevention of IFIs (RR, 0.44 [95% CI 0.28 to 0.70, p\u2009=\u20090.0004]). TSA confirmed the prophylactic benefit of posaconazole against IFIs. Posaconazole is effective in preventing IFIs among immunocompromised patients, particularly those with hematologic malignancies and recipients of allogenic hematopoietic stem cell transplantation.<\/jats:p>","DOI":"10.1038\/s41598-020-71571-0","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T10:04:10Z","timestamp":1599127450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Tse Yee","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Shen","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajesh Kalkandi","family":"Veettil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Se","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopinath","family":"Divya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Mooi","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit Kunnath","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"issue":"1","key":"71571_CR1","first-page":"175","volume":"3","author":"J Kriengkauykiat","year":"2011","unstructured":"Kriengkauykiat, J., Ito, J. I. & Dadwal, S. S. Epidemiology and treatment approaches in management of invasive fungal infections. Clin. Epidemiol. 3(1), 175\u2013191 (2011).","journal-title":"Clin. Epidemiol."},{"issue":"Suppl 5","key":"71571_CR2","doi-asserted-by":"publisher","first-page":"S352","DOI":"10.1093\/cid\/ciu639","volume":"59","author":"JR Perfect","year":"2014","unstructured":"Perfect, J. R., Hachem, R. & Wingard, J. R. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin. Infect. Dis. 59(Suppl 5), S352\u2013S355 (2014).","journal-title":"Clin. Infect. Dis."},{"issue":"19","key":"71571_CR3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2146\/ajhp080325","volume":"66","author":"J Menzin","year":"2009","unstructured":"Menzin, J. et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am. J.. Health Syst. Pharm. 66(19), 1711\u20131717 (2009).","journal-title":"Am. J.. Health Syst. Pharm."},{"issue":"18","key":"71571_CR4","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","volume":"71","author":"C Lass-Fl\u00f6rl","year":"2011","unstructured":"Lass-Fl\u00f6rl, C. Triazole antifungal agents in invasive fungal infections. Drugs. 71(18), 2405\u20132419 (2011).","journal-title":"Drugs."},{"issue":"12","key":"71571_CR5","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1086\/523576","volume":"45","author":"V Nagappan","year":"2007","unstructured":"Nagappan, V. & Deresinski, S. Posaconazole: A broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 45(12), 1610\u20131617 (2007).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"71571_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2146\/ajhp070532","volume":"66","author":"MI Morris","year":"2009","unstructured":"Morris, M. I. Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am. J. Health Syst. Pharm. 66(3), 225\u2013236 (2009).","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"8","key":"71571_CR7","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","volume":"41","author":"DJ Diekema","year":"2003","unstructured":"Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N. & Pfaller, M. A. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41(8), 3623\u20133626 (2003).","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"71571_CR8","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1128\/AAC.00163-06","volume":"50","author":"F Sabatelli","year":"2006","unstructured":"Sabatelli, F. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50(6), 2009\u20132015 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"71571_CR9","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano, L. et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 91(8), 1068\u20131075 (2006).","journal-title":"Haematologica"},{"issue":"8","key":"71571_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis, D. P. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: Overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 50(8), 1091\u20131100 (2010).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"71571_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","volume":"39","author":"JJ Vehreschild","year":"2013","unstructured":"Vehreschild, J. J. et al. Mucormycosis treated with posaconazole: Review of 96 case reports. Crit. Rev. Microbiol. 39(3), 310\u2013324 (2013).","journal-title":"Crit. Rev. Microbiol."},{"issue":"4","key":"71571_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348\u2013359 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"71571_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann, A. J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335\u2013347 (2007).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"71571_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/TP.0b013e3182577485","volume":"94","author":"AM Chaftari","year":"2012","unstructured":"Chaftari, A. M. et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation 94(3), 302\u2013308 (2012).","journal-title":"Transplantation"},{"issue":"9","key":"71571_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.5414\/CP201880","volume":"51","author":"Y Shen","year":"2013","unstructured":"Shen, Y. et al. Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: A multicenter, randomized, open-label study. Int. J. Clin. Pharmacol. Ther. 51(9), 738\u2013745 (2013).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"71571_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","volume":"77","author":"DJ Epstein","year":"2018","unstructured":"Epstein, D. J. et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. J. Infect. 77(3), 227\u2013234 (2018).","journal-title":"J. Infect."},{"key":"71571_CR17","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. hhtp:\/\/www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"issue":"4","key":"71571_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 151(4), 264\u2013269 (2009).","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"71571_CR19","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw, B. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin. Infect. Dis. 46(12), 1813\u20131821 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"71571_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C. et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366, l4898 (2019).","journal-title":"BMJ"},{"issue":"7109","key":"71571_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109), 629\u2013634 (1997).","journal-title":"BMJ"},{"issue":"1","key":"71571_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/ije\/dyn179","volume":"38","author":"K Thorlund","year":"2009","unstructured":"Thorlund, K. et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. Int. J. Epidemiol. 38(1), 276\u2013286 (2009).","journal-title":"Int. J. Epidemiol."},{"issue":"8","key":"71571_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","volume":"61","author":"J Brok","year":"2008","unstructured":"Brok, J., Thorlund, K., Gluud, C. & Wetterslev, J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J. Clin. Epidemiol. 61(8), 763\u2013769 (2008).","journal-title":"J. Clin. Epidemiol."},{"key":"71571_CR24","unstructured":"Thorlund, K. et al. Software for trial sequential analysis (TSA) ver. 0.9.5.5 Beta. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, free-ware. http:\/\/www.ctu.dk\/tsa."},{"key":"71571_CR25","first-page":"1","volume-title":"User manual for trial sequential analysis (TSA). Copenhagen Trial Unit","author":"K Thorlund","year":"2011","unstructured":"Thorlund, K. et al. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit 1\u2013115 (Centre for Clinical Intervention Research, Copenhagen, 2011)."},{"issue":"7454","key":"71571_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins, D. et al. Grading quality of evidence and strength of recommendations. BMJ 328(7454), 1490 (2004).","journal-title":"BMJ"},{"issue":"7650","key":"71571_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt, G. H. et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650), 924\u2013926 (2008).","journal-title":"BMJ"},{"key":"71571_CR28","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne, J. A. C. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343, d4002 (2011).","journal-title":"BMJ"},{"issue":"1","key":"71571_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1128\/AAC.01985-15","volume":"60","author":"YJ Zhao","year":"2015","unstructured":"Zhao, Y. J. et al. Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis. Antimicrob. Agents Chemother. 60(1), 376\u2013386 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"71571_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/jcpt.12579","volume":"42","author":"LP Leonart","year":"2017","unstructured":"Leonart, L. P. et al. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients. J. Clin. Pharm. Ther. 42(5), 530\u2013538 (2017).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"8","key":"71571_CR31","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1128\/AAC.00355-18","volume":"62","author":"CH Lee","year":"2018","unstructured":"Lee, C. H., Lin, C., Ho, C. L. & Lin, J. C. Primary fungal prophylaxis in hematological malignancy: A network meta-analysis of randomized controlled trials. Antimicrob. Agents Chemother. 62(8), e00355-e418 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"71571_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2147\/IDR.S203579","volume":"12","author":"HC Su","year":"2019","unstructured":"Su, H. C., Hua, Y. M., Feng, I. J. & Wu, H. C. Comparative effectiveness of antifungal agents in patients with hematopoietic stem cell transplantation: A systematic review and network meta-analysis. Infect. Drug Resist. 12, 1311\u20131324 (2019).","journal-title":"Infect. Drug Resist."},{"issue":"1","key":"71571_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","volume":"30","author":"JE Nett","year":"2016","unstructured":"Nett, J. E. & Andes, D. R. Antifungal agents: Spectrum of activity, pharmacology, and clinical indications. Infect. Dis. Clin. N. Am. 30(1), 51\u201383 (2016).","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"3","key":"71571_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dki473","volume":"57","author":"C Charlier","year":"2006","unstructured":"Charlier, C. et al. Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years?. J. Antimicrob. Chemother. 57(3), 384\u2013410 (2006).","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"71571_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/315193","volume":"181","author":"KA Marr","year":"2000","unstructured":"Marr, K. A., Seidel, K., White, T. C. & Bowden, R. A. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181(1), 309\u2013316 (2000).","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"71571_CR36","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth, F., Lockhart, S. R., Berkow, E. L. & Calandra, T. Changes in the epidemiological landscape of invasive candidiasis. J. Antimicrob. Chemother. 73(Suppl 1), i4-13 (2018).","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"71571_CR37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12879-019-3901-y","volume":"19","author":"JC Valentine","year":"2019","unstructured":"Valentine, J. C. et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005\u20132016. BMC Infect. Dis. 19(1), 274 (2019).","journal-title":"BMC Infect. Dis."},{"issue":"12b","key":"71571_CR38","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/imj.12595","volume":"44","author":"S Fleming","year":"2014","unstructured":"Fleming, S. et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern. Med. J. 44(12b), 1283\u20131297 (2014).","journal-title":"Intern. Med. J."},{"issue":"7","key":"71571_CR39","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","volume":"14","author":"LR Baden","year":"2016","unstructured":"Baden, L. R. et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 14(7), 882\u2013913 (2016).","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"71571_CR40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson, T. F. et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 63(4), e1-60 (2016).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"71571_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff, S. C. et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann. Hematol. 97(2), 197\u2013207 (2018).","journal-title":"Ann. Hematol."},{"issue":"7","key":"71571_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1099\/jmm.0.46548-0","volume":"55","author":"DA Enoch","year":"2006","unstructured":"Enoch, D. A., Ludlam, H. A. & Brown, N. M. Invasive fungal infections: A review of epidemiology and management options. J. Med. Microbiol. 55(7), 809\u2013818 (2006).","journal-title":"J. Med. Microbiol."},{"issue":"Suppl 6","key":"71571_CR43","doi-asserted-by":"publisher","first-page":"S604","DOI":"10.1093\/cid\/civ814","volume":"61","author":"D Aguilar-Zapata","year":"2015","unstructured":"Aguilar-Zapata, D., Petraitiene, R. & Petraitis, V. Echinocandins: The expanding antifungal armamentarium. Clin. Infect. Dis. 61(Suppl 6), S604\u2013S611 (2015).","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl 1","key":"71571_CR44","doi-asserted-by":"publisher","first-page":"i60","DOI":"10.1093\/jac\/dkx450","volume":"73","author":"DJ Epstein","year":"2018","unstructured":"Epstein, D. J., Seo, S. K., Brown, J. M. & Papanicolaou, G. A. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. J. Antimicrob. Chemother. 73(Suppl 1), i60-72 (2018).","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"71571_CR45","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10096-014-2287-4","volume":"34","author":"JF Wang","year":"2015","unstructured":"Wang, J. F., Xue, Y., Zhu, X. B. & Fan, H. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: A meta-analysis of RCTs. Eur. J. Clin. Microbiol. Infect. Dis. 34(4), 651\u2013659 (2015).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"7","key":"71571_CR46","doi-asserted-by":"publisher","first-page":"e0180050","DOI":"10.1371\/journal.pone.0180050","volume":"12","author":"CH Lee","year":"2017","unstructured":"Lee, C. H. et al. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials. PLoS ONE 12(7), e0180050 (2017).","journal-title":"PLoS ONE"},{"key":"71571_CR47","unstructured":"Merck & Co., Inc. Noxafil\u00ae (posaconazole) package insert (Merck & Co., Inc., Whitehouse Station)."},{"issue":"9","key":"71571_CR48","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/jac\/dks189","volume":"67","author":"J Auberger","year":"2012","unstructured":"Auberger, J. et al. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: Real-life data from a single-centre institutional retrospective observational study. J. Antimicrob. Chemother. 67(9), 2268\u20132273 (2012).","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"71571_CR49","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/AAC.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna, G., Moton, A., Ma, L., Medlock, M. M. & McLeod, J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53(3), 958\u2013966 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"71571_CR50","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/AAC.03050-14","volume":"58","author":"RF Duarte","year":"2014","unstructured":"Duarte, R. F. et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob. Agents Chemother. 58(10), 5758\u20135765 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"71571_CR51","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jac\/dkv380","volume":"71","author":"OA Cornely","year":"2016","unstructured":"Cornely, O. A. et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J. Antimicrob. Chemother. 71(3), 718\u2013726 (2016).","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"71571_CR52","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1128\/AAC.02686-13","volume":"58","author":"J Maertens","year":"2014","unstructured":"Maertens, J. et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob. Agents Chemother. 58(7), 3610\u20133617 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"71571_CR53","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/jac\/dkx263","volume":"72","author":"OA Cornely","year":"2017","unstructured":"Cornely, O. A. et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J. Antimicrob. Chemother. 72(12), 3406\u20133413 (2017).","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71571-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:57:46Z","timestamp":1670349466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71571"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71571-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"5 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14575"}}